NCT07102901

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability and Efficacy of SHR2554 Tablets in Combination With Other Antitumor Therapies in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 351 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Conditions

• Advanced Gastric Cancer
• Metastatic Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	SHR2554 Tablets	Oral SHR2554 tablets.
DRUG	SHR-A1811 Injection	SHR-A1811 for injection.
DRUG	SHR-A1904 Injection	SHR-A1904 for injection.
DRUG	SHR-1701 Injection	SHR-1701 injection

Timeline

• Start date: 2025-09-05
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-08-05
• Last updated: 2025-09-10

Locations

2 sites across 1 country: China